Trials / Recruiting
RecruitingNCT07053891
LUPKYNIS Drug-use Results Survey
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Voclosporin (LUPKYNIS) | In general, for adults, voclosporin should be administered orally at a dose of 23.7 mg BID. The dosage may be appropriately reduced depending on the patient's condition. In principle, at the start of treatment with voclosporin, it should be used in combination with corticosteroids and mycophenolate mofetil. |
Timeline
- Start date
- 2025-09-17
- Primary completion
- 2031-06-30
- Completion
- 2032-06-30
- First posted
- 2025-07-08
- Last updated
- 2025-09-19
Locations
1 site across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07053891. Inclusion in this directory is not an endorsement.